Drug intelligence / Profile preview

EMP-013

Development stage: Preclinical
Lead developer: Empirico
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

EMP-013 is a small interfering RNA (siRNA) therapeutic developed by Empirico. It is in preclinical development and targets immune system diseases, with a particular focus on inflammation. The specific molecular target and mechanism of action have not been disclosed publicly as of the latest available update. The drug is designed to modulate gene expression via RNA interference, which typically results in the silencing of disease-associated genes relevant to immune or inflammatory pathways[1][2].

Targets

ASGPR (Asialoglycoprotein Receptor 1)

Beyond the preview

Go deeper on EMP-013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EMP-013.

Explore the full profile